NUVL250117C90000
- 0.05
- -0.37-88.10%
Nuvalent Newsroom
Nuvalent Analyst Ratings
H.C. Wainwright Initiates Nuvalent(NUVL.US) With Buy Rating, Announces Target Price $110
Jefferies Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $137
Barclays Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $100
J.P. Morgan Reaffirms Their Buy Rating on Nuvalent (NUVL)
Nuvalent's Promising ALK and ROS1 Programs Drive Buy Rating Amid Strong Financial Position and Upcoming Trials
BMO Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $134
TD Cowen Maintains Nuvalent(NUVL.US) With Buy Rating
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $132
Nuvalent Is Maintained at Outperform by BMO Capital
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $100 to $134
Nuvalent Analyst Ratings
BMO Capital Maintains Outperform on Nuvalent, Raises Price Target to $134
Barclays Remains a Buy on Nuvalent (NUVL)
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)
Nuvalent: Strategic Progress and Pipeline Advancements Solidify Buy Rating
Nuvalent Initiated at Neutral by UBS
UBS Initiates Coverage On Nuvalent With Neutral Rating, Announces Price Target of $100
Nuvalent Is Maintained at Overweight by JP Morgan
Nuvalent Analyst Ratings